化疗相关肝损伤的可逆性
本研究回顾性分析429例因结直肠癌肝转移行524次肝切除患者的化疗相关肝损伤(CALI)可逆性。化疗结束至手术间隔中位56天(15-1264天);间隔<270天各组CALI患病率无显著差异;间隔>270天组(n=31)2-3级窦状隙扩张(SOS)和结节性再生性增生(NRH)发生率较低,脂肪变性和脂肪性肝炎各组相似。47例无间隔化疗再次肝切除患者中,仅间隔>270天组(n=15)2-3级SOS 4/5例消退、NRH 7/8例消退,脂肪变性和脂肪性肝炎持续存在。结论:CALI在化疗后长期持续,SOS和NRH仅在停化疗九个月后消退,脂肪变性和脂肪性肝炎持续存在。
要点
- 化疗结束至手术间隔>270天是2-3级SOS的独立保护因素(p=0.009)。
- 间隔>270天组2-3级SOS 19.4% vs 40.0%(p=0.022),NRH 6.5% vs 20.1%(p=0.063)。
- 无间隔化疗再次肝切除者中,间隔>270天组2-3级SOS 4/5例消退、NRH 7/8例消退,脂肪变性和脂肪性肝炎持续存在。
核心结论
- CALI在化疗后长期持续。
- SOS和NRH仅在停化疗九个月后消退,而脂肪变性和脂肪性肝炎持续存在。
研究设计与样本
- 回顾性分析因结直肠癌肝转移行肝切除、术前接受奥沙利铂和/或伊立替康为基础化疗的患者。
- 共分析429例患者的524次肝切除。
- 按化疗结束至肝切除时间分层并测试多个可能截断值,比较各组CALI患病率。
- 比较47例无间隔化疗再次肝切除患者两次标本的CALI。
主要发现
- 化疗-手术间隔中位56天(15-1264天)。
- 间隔<270天各组CALI患病率无显著差异。
- 间隔>270天组(n=31)2-3级SOS发生率为19.4% vs 40.0%(p=0.022),NRH为6.5% vs 20.1%(p=0.063),脂肪变性和脂肪性肝炎各组相似。
- 化疗-手术间隔>270天是2-3级SOS的独立保护因素(p=0.009)。
- 47例无间隔化疗再次肝切除患者中,仅间隔>270天组(n=15)CALI有差异:2-3级SOS 4/5例消退、NRH 7/8例消退,脂肪变性和脂肪性肝炎持续存在。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chemotherapy-associated liver injury (CALI) increases the risk of liver resection and may prejudice further surgery and chemotherapy. The reversibility of CALI is therefore important; however, no data concerning this are available. This study aimed to retrospectively analyze the reversibility of CALI in patients undergoing liver resection for colorectal metastases. METHODS: All resections of colorectal liver metastases after oxaliplatin and/or irinotecan-based chemotherapy were included. First, liver resections were stratified by time between end of chemotherapy and hepatectomy and several possible cut-off values tested. CALI prevalence in various groups was compared. Second, CALI in the two specimens from each patient who had undergone repeat liver resections without interval chemotherapy were compared. RESULTS: Overall, 524 liver resections in 429 patients were analyzed. The median interval chemotherapy-surgery was 56days (15-1264). CALI prevalence did not differ significantly between groups with a chemotherapy-surgery interval <270days. Grade 2-3 sinusoidal dilatation (SOS, 19.4% vs. 40.0%, p=0.022) and nodular regenerative hyperplasia (NRH, 6.5% vs. 20.1%, p=0.063) occurred less frequently in patients with an interval >270days (n=31); prevalence of steatosis and steatohepatitis was similar in all groups. A chemotherapy-surgery interval >270days was an independent protector against Grade 2-3 SOS (p=0.009). Forty-seven patients had repeat liver resection without interval chemotherapy. CALI differed between surgeries only for a chemotherapy-surgery interval >270days (n=15), Grade 2-3 SOS having regressed in 4/5 patients and NRH in 7/8; whereas steatosis and steatohepatitis had persisted. CONCLUSIONS: CALI persists for a long time after chemotherapy. SOS and NRH regress only after nine months without chemotherapy, whereas steatosis and steatohepatitis persist. LAY SUMMARY: The patients affected by colorectal liver metastases often receive chemotherapy before liver resection, but chemotherapy causes liver injuries that may increase operative risks and reduce tolerance to further chemotherapy. The authors analyzed the reversibility of the liver injuries after the chemotherapy interruption. Liver injuries persist for a long time after chemotherapy. Sinusoidal dilatation and nodular regenerative hyperplasia regress only nine months after the end of chemotherapy, whereas steatosis and steatohepatitis persist even after this long interval.
引用
- Vigano L, De Rosa G, Toso C, et al. Reversibility of chemotherapy-related liver injury. J Hepatol. 2017. PMID: 28284915. doi:10.1016/j.jhep.2017.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。